Psoriasis is a chronic auto-immune disease that affects 2-3%of the general population. It is associated with a series of conditions such as psoriasis arthritis, metabolic syndrome, cardiovascular disease, inflammatory bowel disease, psychiatric manifestations. This review aims to highlight the common pathogenic pathway of psoriasis and comorbidities, especially metabolic syndrome (MetS) and, according to the literature, their evolution with systemic therapy.
We conducted an observational study on 51 patients with psoriasis.The metabolic syndrome defined according to National Cholesterol Education şi ATP III criteria (Adult Treatment Panel guidelines), was seen in 54,90% of cases.
The common pathogenic pathway of psoriasis and metabolic syndrome is represented by chronic inflammation and cytokines as TNF alpha and IL 6, IL 17 are seen in both cases. Despite the numerous efforts to elucidate the pathogenesis of MetS, the relation between psoriasis and its different components remains complex and fairly unclear.